Respiratory Clinical Trial Experience
Indications
Administration Routes
For over 40 years, SGS has built up unique expertise in early phase clinical trials including First-In- Human studies, QT/QTc prolongation, human challenge testing, biosimilars and complex PK/PD studies. 158 respiratory clinical trials have been conducted in the past five years, including 45 multi-center clinical trials in respiratory and pulmonary diseases (Phase 1-IV) in the following diseases:
*Other: Smoking cessation, IPF, BOS, Cough, Rhinitis, 16
Intravenous (IV) 2%
Othe r 6%
Subcutaneo us ( SC) 3 %
Tuberculosis , 6
RSV, 2 8
Intranasal 4%
, 7
Lung Cancer
• Respiratory Syncytial Viral Infection (RSV) • COPD • Influenza • Asthma • Cystic fibrosis (CF) • COVID-19 • Pulmonary arterial hypertension (PAH)
• Lung cancer • Tuberculosis • Smoking Cessation/Addiction • Idiopathic pulmonary fibrosis (IPF) • Bronchiolitis obliterans syndrome (BOS)
Intramuscular/Injectio n 5%
PAH, 1 0
COPD, 25
Inhalation ( DPI) 8%
COVID-19, 1 0
Oral 52%
Inhalation
• Cough • Rhinitis
9%
Inhalation ( MDI) 11%
, 23
Asthma, 21
SGS Phase I-IV Clinical Trials Experience (Last 5 years)
Made with FlippingBook Digital Publishing Software